Clinical trials: Head and Neck Squamous Cell Carcinomas
Oropharyngeal Squamous Cell Carcinoma
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating…
- Trial name
- NCT05268614
- Testing
- Radiation therapy, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Florida
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
HNSCC, Head and Neck Cancer
Immunological Function After Radiation With Either Proton or Photon Therapy
This is a pilot prospective observational cohort study, comprising patients with head and neck cancer (HNSCC) treated with standard of care definitive (chemo)radiation either with photons or protons.
- Conditions
- HNSCC, Head and Neck Cancer, Oropharynx Cancer, Hypopharynx Cancer
- Trial name
- PRO-IMMUNO (NCT06016699)
- Testing
- blood draws
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Esophageal Squamous Cell Carcinoma
Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
We conduct the clinical trial to further explore the efficacy and safety of Apatinib combined with chemotherapy in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.
- Trial name
- NCT03224221
- Testing
- Apatinib, fluorouracil and platinum
- Where
- China
- Volunteers
- 189 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during…
- Conditions
- HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
- Trial name
- NCT07741643
- Testing
- Panitumumab-IRDye800, [18F]NOTA-ABY-030
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Carcinoma
XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma
This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in…
- Trial name
- NCT05927844
- Testing
- XH-30002 capsule, Afatiinb tablet
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention…
- Trial name
- NEEDS (NCT04460352)
- Testing
- Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Esophagectomy
- Where
- 12 sites in Canada, Ireland and 3 more
- Volunteers
- 1,020 people
- Sponsor
- Karolinska University Hospital
Early-Stage Oral Squamous Cell Carcinoma
Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial
This is a prospective, single-arm, Phase II clinical trial. The included population consisted of untreated patients with histologically confirmed stage I-II oral squamous cell carcinoma.
- Trial name
- NCT07007364
- Testing
- Adebrelimab Combined With Albumin Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jun Jia
Esophageal Squamous Cell Carcinoma
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The aim of this study is to evaluate the efficacy and safety of the combined treatment with Sacituzumab Tirumotecan in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT07128693
- Testing
- Sacituzumab Tirumotecan in combination with tislelizumab, Sacituzumab Tirumotecan in combination with anlotinib
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Head and Neck Cancer
Open Label, Phase I ZD6474 Head and Neck Cancer Study
The purpose of this study is to determine the maximum tolerated dose of ZD6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.
- Trial name
- NCT00450138
- Testing
- ZD6474 (vandetanib), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sanofi
Head and Neck Squamous Cell Carcinoma
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared…
- Trial name
- NCT05183048
- Testing
- [89Zr]Panitumumab Tracer
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Alabama at Birmingham
Head and Neck Squamous Cell Carcinoma
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT06989671
- Testing
- JMT101, SYS6002, SG001
- Volunteers
- 430 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Early Esophageal Cancer
China Early Esophageal Cancer Cohort
With the development of endoscopy, more and more patients with superficial esophageal squamous cell carcinoma (ESCC) receive endoscopic resection rather than traditional surgery.
- Trial name
- NCT06515964
- Testing
- observational study
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Changhai Hospital
Early Radiation Dermatitis
Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients
Radiation dermatitis is an acute effect of radiation therapy,Especially in the neck skin of head and neck squamous cell carcinomas' patients.The investigators wanted to confirm the benefit of mometasone furoate (MF) in preventing…
- Trial name
- NCT02495064
- Testing
- Mometasone Furoate Cream
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Yao Liao
Squamous Cell Carcinoma of the Head and Neck
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
The purpose of this observational study is to collect real-world data that describes treatment patterns and clinical outcomes in participants with first line recurrent/metastatic squamous cell carcinoma of the head \& neck (1L…
- Trial name
- NCT05123950
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Bristol-Myers Squibb
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient…
- Trial name
- EAGLE (NCT02369874)
- Testing
- MEDI4736, MEDI4736 + Tremelimumab, Standard of Care
- Where
- 168 sites in United States, Argentina and 22 more
- Volunteers
- 736 people
- Sponsor
- AstraZeneca
Oral Cancer, Squamous Cell Carcinoma
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
This is a prospective study involving human participants. Pressure and stretch sensitivity measures between oral cancer patients and healthy subjects will be compared.
- Trial name
- NCT07095608
- Testing
- Pressure and stretch sensitivity testing
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- New York University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.